Shares of CorMedix Inc. (NASDAQ:CRMD – Get Free Report) have been assigned an average recommendation of “Buy” from the eight research firms that are covering the firm, Ratings reports. Seven analysts ...

Stock analysts at Leerink Partners started coverage on shares of CorMedix (NASDAQ:CRMD – Get Free Report) in a report ...

Fintel reports that on March 7, 2025, Leerink Partners initiated coverage of CorMedix (NasdaqGM:CRMD) with a Outperform ...

Leerink analyst Roanna Ruiz initiated coverage of CorMedix (CRMD) with an Outperform rating and $18 price target The firm believes the ...

DefenCath, CorMedix's primary product, has been at the center of the company's recent success. The product, designed for use in outpatient settings, has shown promising signs since its launch.

As of March 4, 2025, the average one-year price target for CorMedix is $16.52/share. The forecasts range from a low of $12.12 to a high of $19.95. The average price target represents an increase ...

We feel now is a pretty good time to analyse CorMedix Inc.'s ( NASDAQ:CRMD ) business as it appears the company may be... BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc ...

DefenCath, CorMedix's primary product, has been at the center of the company's recent success. The product, designed for use in outpatient settings, has shown promising signs since its launch. The ...

BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life ...